Key Takeaways TEM signed a $200M three-way deal with AZN and Pathos to build a multimodal oncology foundation model. The partnership lifts TEM's total remaining contract value to over $1B as of April 2025. TEM also expanded ties with ILMN to advance molecular profiling across all major disease areas.ForTempus AI (TEM) , expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration wit ...

Personalis (PSNL) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Company Participants Caroline Corner - Investor RelationsChristopher Hall - CEO and PresidentAaron Tachibana - CFO & COORichard Chen - Executive VP of R&D and Chief Medical OfficerVidyun Bais - Equity Research - Vice PresidentYuko Oku - Equity Research Associate Conference Call Participants Thomas Flaten - Senior Research AnalystWilliam Bonello - Senior Research AnalystJoseph Stringer - Senior AnalystDaniel Brennan - Senior Equity Research Ana ...

Personalis (PSNL) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Greetings. Welcome to the Personalis First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I would now like to turn the call over to Caroline Corner. Please go ahead. Speaker1 Thank you, operator. Welcome to Personalis' first quarter twenty twenty five earnings ...